Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026

Same author

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

Sample Size Calculation for the ROCI Design.

Statistics in medicine·2026

Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Ver todos los artículos relacionados

Search research articles

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Desarrollo de Fármacos

Sabahat Iqbal¹, Cristina Bonet Olivares¹, Laura Rizzo²

¹Imperial College London, London, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|December 25, 2025

Resumen

Este resumen es generado por máquina.

Se identificó una línea de producción sistemática de fármacos reutilizados prometedores para la enfermedad de Alzheimer (EA). La atomoxetina, la metformina y el mononitrato de isosorbida muestran potencial para ensayos clínicos en pacientes con EA.

Palabras clave:

Enfermedad de Alzheimer reposicionamiento de fármacos ensayos clínicos desarrollo de fármacos atomoxetina metformina mononitrato de isosorbida

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Área de la Ciencia:

Neurociencia
Farmacología
Ensayos clínicos

Sus antecedentes:

Los tratamientos existentes para la enfermedad de Alzheimer (EA) requieren mejoras en eficacia y seguridad.
Existe la necesidad de estrategias terapéuticas novedosas más allá de los agentes que eliminan amiloide.
Los fármacos reutilizados ofrecen una vía potencial para el desarrollo clínico acelerado en la EA.

Objetivo del estudio:

Establecer una línea de producción sistemática y objetiva de fármacos para identificar fármacos reutilizados para la EA.
Identificar compuestos con el mayor potencial de efecto clínico sostenido en pacientes con EA de leve a moderada (MMSE >17).
Seleccionar candidatos para un ensayo de plataforma planificado en el Reino Unido con múltiples brazos.

Principales métodos:

Las propuestas de compuestos obtenidas de la comunidad fueron evaluadas por un panel de expertos internacional.
Los compuestos se clasificaron según datos preclínicos, eficacia, plausibilidad biológica y seguridad.
Las revisiones sistemáticas de la literatura utilizando aprendizaje automático (Repurposing Living Systematic Review) complementaron los datos de los fármacos.

Principales resultados:

La atomoxetina ocupó el primer lugar, la metformina el segundo y el mononitrato de isosorbida/levetiracetam conjuntamente el tercero.
Los factores clave incluyeron vías mecanicistas plausibles en la EA y datos sustanciales de seguridad/tolerabilidad clínica.
Se preseleccionaron ocho compuestos después de la revisión inicial y la compilación de datos.

Conclusiones:

Se desarrolló un enfoque práctico y sistemático para priorizar fármacos reutilizados para la evaluación clínica de la EA.
Los compuestos identificados representan candidatos prometedores para una mayor investigación en ensayos de plataforma.
Los contribuyentes pacientes y públicos fueron integrales al proceso de priorización.